CEBPA antibody - N-terminal region (P100908_P050)
- Known as:
- CEBPA (anti-) - N-terminal region (P100908_P050)
- Catalog number:
- p100908_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- CEBPA antibody - N-terminal region (P100908_P050)
Related genes to: CEBPA antibody - N-terminal region (P100908_P050)
- Gene:
- CEBPA NIH gene
- Name:
- CCAAT enhancer binding protein alpha
- Previous symbol:
- CEBP
- Synonyms:
- C/EBP-alpha
- Chromosome:
- 19q13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1991-11-27
- Date modifiied:
- 2019-04-23
- Gene:
- CEBPA-DT NIH gene
- Name:
- CEBPA divergent transcript
- Previous symbol:
- CEBPA-AS1
- Synonyms:
- -
- Chromosome:
- 19q13.11
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2012-08-10
- Date modifiied:
- 2018-03-22
Related products to: CEBPA antibody - N-terminal region (P100908_P050)
Related articles to: CEBPA antibody - N-terminal region (P100908_P050)
- Pre-pregnancy obesity (ppOB) is linked to pregnancy complications and abnormal fetal growth through placental mechanisms, and long non-coding RNAs (lncRNAs) may play an epigenetic role in these processes. We investigated overall and sex-specific associations of pre-pregnancy body mass index (ppBMI), ppOB, and birthweight with placental lncRNA transcripts in two birth cohorts. Study participants were mother-child dyads recruited to the CANDLE (Memphis, TN)( = 725) and GAPPS (Seattle and Yakima, WA)( = 159) cohorts. Maternal ppBMI was assessed at enrollment using interviewer-administered questionnaires. LncRNAs (1,077 and 1,033 for CANDLE and GAPPS, respectively) were sequenced from placental samples collected at birth. Placental lncRNA was regressed on ppBMI, ppOB (ppBMI ≥30kg/m), or continuous birthweight in cohort-specific weighted linear models controlling for -specified confounders and experimental variables. Potential effect modification by infant-sex was examined in sex-stratified analyses and models including BMI-infant-sex interaction terms. No lncRNA transcripts were significantly associated with ppBMI, ppOB, or birthweight in primary models. Among male infants in CANDLE, expression of three lncRNA transcripts (, , ) was associated with ppBMI and one transcript () with birthweight. In GAPPS, ppBMI was associated with two lncRNA transcripts ( and ) among males, and birthweight was associated with 17 lncRNA transcripts (including , , and ) among females. No BMI-infant-sex interactions were observed. Though many of these potential associations are for uncharacterized transcripts, several identified lncRNAs (e.g., and ) have been linked to pathways controlling cancer or placental growth, trophoblast differentiation, and gene expression. These associations warrant validation in future studies. - Source: PubMed
Publication date: 2025/05/21
Hussey Michael RMacDonald JamesBammler Theo KTekola-Ayele FasilKerr Kathleen FPaquette Alison GMarsit Carmen JLeWinn Kaja ZZhao QiKarr Catherine JSathyanarayana SheelaEnquobahrie Daniel A - Hepatocellular carcinoma (HCC) is the world's third leading cause of cancer-related death; due to the fast growth and high prevalence of tumor recurrence, the prognosis of HCC patients remains dismal. Long non-coding RNA CEBPA-DT, a divergent transcript of the CCAAT Enhancer Binding Protein Alpha (CEBPA) gene, has been shown to participate in multiple tumor progression. However, no research has established its cancer-promoting mechanism in HCC yet. - Source: PubMed
Publication date: 2022/12/06
Cai YunshiLyu TaoLi HuiLiu ChangXie KunlinXu LinLi WeiLiu HuZhu JiangLyu YinghaoFeng XupingLan TianYang JiayinWu Hong - Bipolar disorder (BD) is a mental disorder that leads to abnormal swings in mood, energy, activity level, attention, and the capability to accomplish daily tasks. Several long non-coding RNAs (lncRNAs) are dysregulated in BD patients. We have compared expression levels of five NF-κB-associated lncRNAs, namely ANRIL, CEBPA-DT, H19, NKILA and HNF1A-AS1 in blood samples of BD patients compared with controls. While ANRIL, CEBPA-DT and HNF1-AS1 were significantly under-expressed in BD patients compared with controls, NKILA levels were higher in patients versus controls. Among differentially expressed genes, HFN1A-AS1 exhibited the best diagnostic parameters in the separation of patients from controls (AUC ± SD = 0.86 ± 0.03, sensitivity = 0.82, specificity = 0.82, P value < 0.0001). AUC values for NKILA, ANRIL and CEBPA-DT were 0.71, 0.68 and 0.65, respectively. In accordance with the previously reported participation of NF-ƙB in the pathophysiology of BD, the current study provides evidence for dysregulation of NF-κB-associated lncRNAs in BD. - Source: PubMed
Publication date: 2022/12/03
Teshnizi Sara AhmadiShahani PariyaTaheri MohammadHussen Bashdar MahmudEslami SolatSadeghzadeh ZahraGhafouri-Fard SoudehSayad Arezou - Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer. Chemotherapy has been recognized as an optional combination treatment, which enhance the overall survival of OSCC patients. However, the majority of patients would suffer therapeutic resistance, which led to the treatment failure and poor prognosis. - Source: PubMed
Publication date: 2021/12/02
Qiao XueZhu LiSong RongboShang ChaoGuo Yan - Intrinsic or developing resistance to chemotherapy drugs including cisplatin (CDDP) remains the major limitation of cancer therapeutic efficacy in cancers. Recently, increasing evidence suggested that long noncoding RNAs (lncRNAs) play a critical role in various biological processes of tumors, and have been implicated in resistance to various drugs. However, the role of lncRNAs in cisplatin resistance is poorly understood. Here, we found that the expression of lncRNA CEBPA-DT/CEBPA/BCL2 was upregulated in cisplatin resistance OSCC cells (Cal27-CisR and HSC4-CisR) compared with their parental cells (Cal27 and HSC4). CEBPA-DT overexpression could upregulated both cytoplasmic and nuclear CEBPA expression. Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells. In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis. Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression. Our findings indicate that downregulation of lncRNA CEBPA-DT may be a potential therapy to overcome cisplatin resistance in OSCC. - Source: PubMed
Publication date: 2021/09/27
Qiao XueLiu JiayiZhu LiSong RongboZhong MingGuo Yan